Abstract: Conjugated and unconjugated pteridines and their derivatives are important cofactors in cellular metabolism. Hence, the amount of unconjugated pteridines in biological fluids has been found to be modified as a result of several disorders. It is necessary to note that while for the control of pteridines in urine samples there are numerous reference data, the literature referred to for the analysis of these analytes in serum/plasma is scarce. In biological fluids, pteridines can exist in different oxidation states, and these compounds can be classified into two groups according to: (a) oxidized or aromatic pteridines and (b) reduced pteridines. Oxidized pteridines yield a strong fluorescence signal, whereas reduced pteridines present a low quantum yield of fluorescence. In order to enable the analysis of the reduced forms, several preoxidation procedures to generate aromatic rings have been established. Also, stabilization of the reduced forms by the addition of reducing agents has been widely reported. The objective of this paper is to show possibilities and different approaches in the analysis of pteridines in serum samples. We have mainly focused on the description of the current situation in the application of high-performance chromatography methods with fluorimetric detection.
Introduction
Pteridines and their derivatives are important cofactors in the process of cell metabolism. The amount of these compounds in biological fluids has been found to be modified as a result of several disorders, for example, viral infections, autoimmune diseases, chronic diseases and different types of cancer [1] . Although neopterin (NEO) has been classically considered to be the most important pteridine cancer marker [2] and also as a notable immunology marker [3] , different pteridines can be also used in clinical laboratories for cancer and pre-cancer screening [4] . From this perspective, pteridines can be considered as potential biomarkers. There are data about the basal levels of pteridines in biological fluids [5, 6] , and alterations in these levels have been described as the result of the presence of several diseases. In the particular case of malignant diseases, an ideal situation should be that each type of tumor shows its own pteridinic pattern, and that the alterations in the levels allow an early detection [7] . However, the causes that lead to alterations in the pteridine content in biological fluids are not yet clear.
It is necessary to note that while there are numerous references for the control of pteridines in urine, data about the presence of these analytes in serum/plasma and in other biological fluids are very scarce. The clinical use of the serum pteridinic profile is still surprisingly poorly studied. Also, the few existing data refer to individual determinations, such as the analysis of NEO or biopterin (BIO), but a comprehensive study on the pteridine pattern in serum has not been found. Advances in analytical techniques, mainly chromatographic techniques, applied to the analysis of biological fluids are essential for a deeper understanding of normal pteridine patterns and to establish values that can be considered as pathological.
The complexity of the serum samples as well as the high sensitivity and selectivity required in the analysis of pteridines has limited the progress of new analysis protocols. High-sensitivity spectrofluorimetric techniques coupled to chromatographic systems appear to be a powerful way for studying new methods of analysis.
The purpose on this review is to show an overview of the analysis of serum-unconjugated pteridines, with a special focus on the use of chromatographic techniques with fluorimetric detection.
Chemical characteristics of the pteridines
The compounds being studied are a family of heterocycles formed by a bicyclic pyrimidine-pyrazine that occur in a wide range of living systems and participate in relevant biological functions [8] . The metabolites of interest include pteridines (2-amino-4-hydroxypterin derivatives) and lumazines (LUs, 2,4-dihydroxypterin derivatives). In nature, the most common derivatives are 6-substituted compounds. The molecular weight and functional groups of these derivatives vary considerably, e.g. pteridines may have substituents with one carbon atom, with a short hydrocarbon chain (unconjugated pteridines) or larger substituents containing p-aminobenzoic and glutamic acid moieties named folates. Pteridines can exist in different oxidation states and can be divided into two classes according to this property: (a) oxidized or aromatic pteridines and (b) reduced pteridines, the predominant forms being dihydropteridines and tetrahydropteridines. 7,8-Dihydropteridines and 5,6,7,8-tetrahydropteridines are the most important derivatives because of their biological activity, e.g. 7,8-dihydroneopterin (NH2) is excreted during the oxidative burst in stimulated macrophages and, 7,8-dihydrobiopterin (BH2) and 5,6,7,8-tetrahydrobiopterin (BH4) participate in the metabolism of amino acids. The chemistry of the dihydropteridines has been reported in detail in [9] . Interesting information about pteridines can be found in a specialized web page [10] .
In biological fluids, pteridines are present as fully oxidized aromatic forms and as reduced forms, mainly as 7,8-dihydropteridines and 5,6,7,8-tetrahydropteridines. The chemical structures of the most significant unconjugated pteridines are summarized in Table 1 . Data about the pteridine levels in different biological samples are also shown.
Unsubstituted pteridines are soluble in water, but in general, the inclusion of substituents incorporating hydrogen atoms capable of generating hydrogen bonds into the heterocyclic rings causes a significant decrease in solubility. Thus, the incorporation of hydroxyl or amino groups decreases the solubility of the electron π-deficient heterocycles because the formation of the intramolecular bonds prevents the formation of hydrogen bonds with water [17] .
Fully oxidized forms are strongly fluorescent; however, the reduced forms are the only absorbent species. Pteridines and LUs are yellow pigments with blue fluorescence around an excitation maximum at 370 nm and emission near 450 nm [18] . The fluorescence of pteridines are pHdependent in aqueous solutions, being maximal between pH 4 and 6 for most of them, but high fluorescence is observed for xanthopterin (XAN) and isoxanthopterin (ISO) in basic medium.
Pteridines present in biological medium in the reduced form are non-fluorescent. Biological fluids can be oxidized to transform non-fluorescent pteridines in oxidized fluorescent forms. The most frequent method, the Trehan method [19] , uses iodine/iodide (I 2 /I − ) as the oxidation agent. The oxidation conditions have been widely studied with the aim of optimizing the oxidation period and establishing the percentage of the oxidized form of each pteridine [20] . XAN and BIO are the most affected by the oxidation time; 40 min is considered as optimum for the simultaneous determination of pterin-6-carboxylic acid (PT6C), NEO, XAN, ISO and BIO, with the aim of obtaining the highest fluorescence signals. Instability in XAN and partial oxidation in BIO are observed at longer oxidation times. On the one hand, the NEO/BIO ratio is affected if a short or very long oxidation time is applied. Other oxidation agents, such as permanganate, have also been tested [21] , and in this case, the amounts of PT6C and BIO reported are higher than those reported by the Trehan method; consequently, the NEO/BIO ratio is lower. The Fukushima method, on the other hand, has been widely proposed for the oxidation of BH4 [22] . This procedure involves two steps: 1) by acid I 2 oxidation, BH2 and BH4 give rise to BIO and 2) by alkaline I 2 oxidation, BH4 give rise to pterin (PT) and BH2 to BIO. Hence, the content of BH4 in the original sample is calculated by the difference between the amounts of BIO obtained by acid and alkaline oxidations. Some modifications to this method are intended to prevent the auto-oxidation of BH4 by atmospheric oxygen at room temperature by using antioxidants such as dithioerythriol (DTE) or dithiothreitol (DTT) [12, 23] , but the effect of these reagents in the I 2 oxidation processes is not clear.
Photochemical studies of pteridinic derivatives indicate that changes in the oxidation state of the original PT heterocycles can also be generated by UV photoirradiation, but some substituted pteridines show resistance. 6,7-Dimethyltetrahydropterin was used as a model compound to show that protonation of the reduced PT heterocycle increased its resistance to oxidation and UV irradiation did not accelerate this process [24] . Later, the possibility of generating fluorescent BIO by UV irradiation from BH4 and BH2, in the presence of hydrogen peroxide, was reported [25] . Hence, non-fluorescent reduced pteridines can be transformed into their oxidized fluorescent forms and high-sensitivity fluorimetric techniques can then be applied for their detection in biological fluids.
Role of the pteridines in the human physiological functions and clinical relevance
For several decades, unconjugated pteridines have been widely studied and their roles in different physiological processes have been revealed. In the past, greater focus was placed on NEO and BIO, in both the oxidized and reduced forms; however, other pteridines, such as XAN and PT6C, have recently been gaining popularity.
In humans, BH4 has been recognized as the most important unconjugated pteridine. It is an essential cofactor for aromatic amino acid hydrolases, glyceryl-ether monooxygenase and three nitric oxide synthases [26] , and plays an important role in monoamine neurotransmitter metabolism. Defects in BH4 metabolism and recycling results in BH4 deficiency and neurological deterioration, with progressive mental retardation and other strong physiological alterations [27] .
The diagnosis of these metabolic alterations [28] is based on the determination of neurotransmitters and pteridines, notably BH4, BH2 and NH2, in cerebrospinal fluids. BH4 and diverse pteridines are generated from guanosine-5′-triphosphate (GTP) in humans. In Figure 1 , a schematic metabolism pathway is shown and the generation of five unconjugated pteridins NEO, BIO, XAN, ISO and PT in the oxidized and reduced forms can be observed.
NEO is an oxidative product of dihydroneopterin triphosphate, while BIO is an oxidative product of BH2 and BH4. The diagnosis of BH4 deficit, or enzymatic inefficiency, is usually established by measuring NEO and BIO in body fluids, especially in urine [29] . BH4-deficient hyperphenylalaninemia, generated by alteration of GTP cyclohydrolase, produces a decrease of about 50% in the NEO and BIO amounts; 6-pyruvoyltetrahydropterin synthase (6-PTS) deficiency involves high levels on NEO and very low amounts of BIO; in sepiapterin (SPT) reductase deficiency, both NEO and BIO present normal levels, and dihydropterin reductase deficiency involves a high increase of BIO and normal levels of NEO [30] . In all these, NEO appears as a useful marker in the diagnosis of malignant and inflammatory diseases [31] .
Alterations in the normal amounts of several pteridines in urine as a consequence of several disorders have been reported. For instance, higher levels of BIO were found in autistic children compared with a control group [32] . Increased amounts of XAN, NEO, PT and the NEO/ BIO ratio were reported in cancer patients [33] . NEO concentration was correlated with a decline in Alzheimer's disease patients [34] and in acute coronary syndrome [35] . An increase in PT6C and a decrease in ISO were also reported in cancer patients [36] . Moreover, BH2, BIO and other PT derivatives have been found in the skin of patients suffering from vitiligo [37] . Increments in the NEO/creatinine (CREA) ratio were significant in psoriatic patient [38] . 7-Biopterin (7BIO) is excreted by patients with carbinolamine dehydratase deficiency [30] , and the levels of 6-hydroxymethylpterin (6HMPT) in urine increase in cerebral tumor patients [39] .
Although urinary excretion of the pteridines has been mostly established, the levels in other biological media as ascitic fluids [40] , saliva [41] , tears [42] , cerebrospinal fluid [43, 44] and intracellular media [13] are also has interest from the point of view of clinical applications.
Analysis of pteridines in biological fluids
The importance of the analysis of pteridines in urine samples is well known. Several papers have recently been published containing information about the determination of pteridines, including data about their analysis in healthy and pathological urine [45] . In most of the mentioned papers, a large number of pteridines has been analyzed, and separation techniques such as high-performance liquid chromatography (HPLC) using fluorimetric detection [46] , HPLC-mass spectrometry (MS) [15] , HPLC-MS/MS [16, 47] and capillary electrophoresis with laser-induced fluorescence (CE-LIF) [36] were widely applied. However, the determination of pteridines in serum/plasma samples is a scarce topic of research.
In the literature, the determination of only one or two pteridines in serum or plasma is frequent, but less data on the analysis of a large number of pteridines present in the serum samples are present. A recent review explored the importance of pteridine determination in biological 2-Aminopteridin-4-one derivatives
fluids [48] , and contained remarkable data about the pretreatment and determination of pteridines in different biological fluids including serum. Below, this review chronologically describes HPLC methods with fluorimetric detection for pteridine analysis.
There are many problems in the analysis of pteridines in serum samples that decisively influence the fact that available data on pteridines in serum samples are lower than in urine samples. These are related with the great complexity of the serum matrix, and some of the main problems are the lower amounts of these compounds in serum, the high protein contents and the large number of potentially interfering compounds and the scarce information about the stability of the pteridines as reduced forms in this medium.
Aspects related to stability of the pteridines and sample preparation
Reduced pteridines, dihydro-and tetrahydropteridines exhibit low stability in solution and strongly depend on the medium conditions such as acidity, environmental oxygen and environmental light. At neutral pH, reduced forms are easily oxidized by molecular oxygen giving rise to fluorescent forms. Hence, for example, in the standard solution of the dihydropteridines, a notable amount of oxidized pteridines are always present. In biological fluids, pteridines are present as a mixture of reduced and oxidized forms. To establish the serum pteridine pattern involves the identification of all existing pteridine forms, but maintaining the reduced forms in their natural oxidation state is very difficult.
Several protected agents have been used in the analysis of pteridines: ascorbic acid, DTE and DTT [12] , the last being currently the most recommended. Special caution must be taken into account in the analysis of BH4 and BH2. Sample collection should be carried out in tubes containing DTT or similar reagents. The conjunction with a frozen process is also widely recommended. In the absence of DTT, even the frozen sample suffers from oxidation. Protection from sunlight is also necessary. To prepare standard solutions of BH4 and BH2, the presence of 0.1% DTT and daily preparation are strongly recommended. Similar precautions should be taken into account in the preparation of NH2 standard solutions.
Serum sample preparation, prior to the application of HPLC methods, is laborious due to the necessity of eliminating proteins. On the other hand, it is simultaneously necessary to prevent the oxidation of the pteridinic reduced forms. Normally, the first step is precipitation using several chemical reagents such as trichloroacetic acid (TCA) or perchloric acid, accomplished with an oxidation step using I 2 /I − solution [22] . In some cases, only denaturalization by heating is proposed.
Bibliographic references about serum/plasma sample analysis
The focus of a researcher's interest has been on only one or two pteridines, NEO and BIO being the most frequently R R′ Name (acronym) analyzed pteridines in serum/plasma samples. NEO is considered as an important biomarker in clinical diagnosis and a serum NEO concentration of 10 nmol L −1 is accepted as the upper normal limit [49] . The levels of this pteridine have been also correlated with age and with gender. It has been established that NEO concentration in serum shows a slight increase with age but not with sex.
Several LC techniques have been proposed for the analysis of these compounds in serum samples, and the methods better suited for this are those that use fluorescence as an analytical signal. Hence, one of the most used methods was proposed by Fukushima and Nixon for the determination of BIO and other unconjugated pteridines, such as NEO, in blood and in other biological fluids and tissues [22] . The procedure consists of an initial I 2 oxidation of the reduced forms of BIO, followed by a partial purification on a Dowex 50 column and subsequent fluorimetric HPLC analysis. Quantification limits at picomole levels are reported. The oxidation method, described in detail in this paper, has been widely used in the subsequent years.
Using reversed-phase (RP) HPLC, up to 10 pteridines (PT6C, XAN, NEO, MON, ISO, LU, BIO, 6-HMPT, PT and 6-MPT) have been separated in blood extracts and determined fluorimetrically [50] . Aerial oxidation of blood at 100 °C and at 120 °C was fluorimetrically monitored. The amount and nature of the pteridines detected in human blood are strongly affected by the temperature and heating time of the releasing procedure. In addition, three SPTs can also be analyzed in human blood plasma. A long consuming time per sample is reported as 38 min are necessary for only one chromatographic run. Although prior chemical oxidation is not applied, only oxidized forms are determined and data about reduced forms are not reported. The most abundant pteridine concentrations in blood were XAN (1240 pg mL −1 ) and NEO (1050 pg mL −1 ). These amounts were calculated by heating for 20 min at 100 °C. No data about the repetitivity are reported; however, this paper provides notable information about the analysis of pteridines in blood.
Several modifications in the previous treatment of the samples, mainly in the oxidation process, have been reported to analyze only NEO or the NEO/BIO ratio.
Hence, NEO and CREA were simultaneously determined in serum using HPLC and fluorimetric detection [51] . In this paper, a combination of solid-phase extraction (SPE) and HPLC with online elution has been described. Also, serum NEO concentrations were measured by radioimmunoassay (RIA) and the results compared. No differences were found in the 90 blood donor groups. Values of 52.7 and 73.8, expressed as μmol mol −1 (NEO/CREA ratio), were obtained for males and females, respectively. The detection limit in the serum sample was 0.5 nmol L −1
. Precipitation of proteins is avoided by using SPE cleaning (propylbenzenesulfonic-acid-modified sorbent strong cationic exchange [SCX] ) and the analytes were eluted directly onto the column. In this case, the preoxidation of the potential reduced forms has not been carried out. Another method, without sample preparation or oxidation, has been proposed for the analysis of NEO in serum samples. Samples were ultrafiltered through membranes that allow the passage of particles with a relatively low molecular mass and centrifuged, and the ultrafiltrate was analyzed. The HPLC results were compared with results obtained by RIA, obtaining a good correlation between both methods. This HPLC method reports the determination of only NEO, but the proposed online SPE separation is very interesting. Figure 2 shows the schematic diagram of the SPE cartridge coupled to the fluorimetric HPLC system [51] . Rapid HPLC methods for measuring BIO and NEO [52] and NEO in serum [53] have been proposed. In the first paper, samples were acidified, treated with I 2 in 0.2 mol L −1 TCA, partly purified on Bio-Rad MP-50 cationexchange columns, and analyzed by RP HPLC with fluorimetric detection. The mean observed values for BIO and NEO in the sera of normal human adults were 1.64 and 5.52 μg/L (NEO/BIO ratio = 3.23), respectively. The reported method was assayed in serum or plasma from six patients with hyperphenylalaninemia and one with tyrosinemia. In these pathologies, both pteridines are considered as the most important clinical markers. Values of NEO/ BIO ratios of 0.33-0.82 in phenylketonuria (PKU), 4.32 in atypical PKU and 0.58 in tyrosinosis type II were reported, and these data are in concordance with those previously reported.
Oxidized NEO was determined in serum samples, previously removing NH2 with ferric nitrate/EDTA solution [54] ; hence, the authors avoid deproteinization, which may lead to the degradation of NEO. Solid-phase propylbenzenesulfonic acid minicolumns was used for cleaning before fluorimetric RP HPLC determination, using 6-methylpterin as an internal standard. The limit of detection (LD) was 0.75 nmol L −1
. In healthy subjects, the NEO level in serum was <10 nmol L −1 and in bone marrow transplant patients, the NEO level ranged between 10 and 20 nmol L −1 . An interesting method based on a RP ion pair LC system has been also proposed to analyze 6R-BH4, 6S-BH4, NEO, BIO and BH2 in tissues [55] such as brain, kidney and liver of rats. The possibility of differentiating between the S and R enantiomer forms has been sparingly described in the literature. In [55] , the authors also propose a post-column nitrite oxidation for generating the fluorescent forms. The detection limit was 10-20 pg using the signal-two-noise ratio of 3 as the criterion. The system was proposed to be adequate to monitor dialysates collected in vivo. This work is almost the only one related to the separation of R/S derivatives. A schematic diagram of the post-column oxidation coupled to a fluorimetric HPLC system proposed is shown in Figure 3 .
Another procedure for the analysis of NEO in serum samples was carried out by two-dimensional chromatography with column switching, using two separation columns with different selectivities [56] . In the first dimension, NEO was separated from most of the serum components, such as serum proteins and less-polar serum constituents. In the second dimension, solventgenerated ion exchange, using dodecylsulfonic acid as an additive in the mobile phase was used and NEO was detected at 438 nm (excitied at 353 nm) (Figure 4 ). Complex gradient programs for elution and column cleaning are applied. The detection limit was 0.3 nmol L −1 using a signal-to-noise ratio of 3. A comparison of the HPLC and RIA results was made and the authors assume that HPLC is more accurate than RIA and can be used as a reference method.
NEO levels have been correlated with the concentration of other analytes present in serum, with the aim of establishing NEO/analyte ratios in healthy subjects. A RP-HPLC-fluorimetric method has been applied to establish the relation between the content of NEO and homocysteine in serum samples of healthy volunteers [57] . Good correlation was observed between the amount of NEO measured by enzyme-linked immunosorbent assay (ELISA) and HPLC. In this case, the protein precipitation was carried out with perchloric acid and then neutralized aliquots of the supernatant were injected in the system. Comparability of the results obtained from acid-deproteinized sera with the results of the ELISA test where serum is directly used indicate that removal of proteins by acid before analysis does not cause a significant loss of NEO. The mean content (n = 40 volunteers) of NEO was 7.5 ± 0.4 nmol L −1 . In the same way, the relationship between NEO and thiol content in plasma has been established using TCA protein precipitation [58] . Adapted from [55] .
The second target pteridine in serum samples and the focus of much research has been BIO. As the reported values of total BIO in the plasma of healthy controls show large variations (6.9-23.6 nmol L −1 ), both BH4 and total BIO in plasma have been determined by means of RP-HPLC with fluorimetric detection [12] . The authors propose a modification of the Fukushima and Nixon method using DTT as an antioxidant to prevent the oxidation of the reduced form. The use of DTT appears to be an important contribution to the stabilization of reduced forms and it has been widely applied for several studies.
However, some authors have proved that the presence of DTT could interfere in the I 2 oxidation process. As an alternative, an offline photooxidation process in the presence of hydrogen peroxide at trace levels has been proposed to calculate total BIO in serum samples [25] . The proposed HPLC fluorimetric method allows the resolution of BH4 and BIO in the same sample by injection in the chromatographic system of non-irradiated and irradiated aliquots. The detection was scanned at the most sensitivity-exciting wavelength, λ ex /λ em = 272 nm/440 nm, instead of λ ex /λ em = 353 nm/438 nm previously reported. A semiautomatic online photooxidation HPLC fluorimetric system for BH4, BH2, BIO and other pteridine markers has been applied for the analysis of urine, but the application in serum is yet to be developed.
On the other hand, and with the aim of providing an alternative to the chemical oxidation of pteridines prior to fluorimetric detection, the use of sequential electrochemical and fluorimetric detection has been proposed by Hyland [59] . This author proposes the use of an octadecyl silica (ODS) RP column, an ESA coulometric dual-cell electrochemical detector and a second fluorimetric detector. Tetrahydropterins are estimated electrochemically, dihydropterins by fluorescence detection following postcolumn electrochemical oxidation and the oxidized pteridines directly by their natural fluorescence. The proposed method was tested in urine samples but not in serum samples. Biondi et al. [60] also used a similar system to analyze the reduced and oxidized forms of pteridines using sequential electrochemical oxidation and fluorimetric detection. This alternative method could be interesting for the analysis of biological fluids, as the authors indicate, but they do not provide data for use in serum or plasma.
Recently, a RP-HPLC-fluorimetric method was developed to establish the serum pteridine pattern [11] . In this paper, proteins were removed by precipitation with TCA, and the I 2 oxidation method was applied for the determination of pteridines. The neutralized supernatant was cleaned by passing through a hydroxylated polystyrenedivinylbenzene copolymer cartridge. The retained pteridines were eluted with acetonitrile-water (80:20, v:v) and the eluate was evaporated to dryness under a stream of nitrogen (N 2 ). A fast-scanning fluorimetric detector allows recording the signal in multi-emission mode; a notable (after immediate collection of the sample, n = 4) [12] increase of the sensitivity is thus obtained because each pteridine is monitored at the most favorable wavelength emission (410, 445 and 465 nm), excited at 272 nm. Moreover, the use of a solid core RP-Poroshell column provides the necessary resolution. Eight pteridines were determined in previously oxidized serum samples of healthy persons and detection limit values (using the Long and Winefordner criterion) between 0.23 and 0.47 ng mL −1 were reported. The limitation of this paper is that the reduced pteridines cannot be determined. In Table 2 , the literature referred to for the HPLC fluorimetric analysis of serum pteridines have been summarized.
Future perspectives
In relation with the development of fluorimetric HPLC techniques for the analysis of serum pteridines, different techniques could be employed, based on the current situation of research in this field and in the achievements in the analysis of pteridines in other biological fluids more profusely studied, such as urine samples.
First, modifications in the retention system, such as the use of hydrophilic interaction chromatography (HILIC) chromatography, may be assayed in serum samples. Recently, this approach has been proposed as an alternative to the RP LC separation of polar, weakly acidic or basic samples, and an interesting review has been published [61] . The term hydrophilic refers to an affinity for water, and HILIC is a chromatographic technique using a normal stationary phase in combination with a reversed mobile phase, containing more than 50% of organic solvent in water [61] . Due to the lower organic mobile phase viscosity, a better efficacy could be obtained for the separation of polar compounds. On the other hand, HILIC shows advantages for coupling with MS [62] .
A study based on the HILIC approach using hybrid stationary phases in ultra-HPLC (UHPLC) systems with fluorimetric detection for the separation of NEO, BIO, NH2 and BH2 was conducted [63] . A HILIC-bridged ethyl hybrid amide column provides adequate selectivity for the separation of the four selected pteridines, but biological fluids have not been tested. Recently, determination of pteridines, in previously oxidized urine samples, using several types of chromatographic stationary phases, including HILIC, has been reported [64] . However, in this paper, the best results were obtained using an RP C8 column. On the other hand, the combination of HILIC and an RP system in two-dimensional HPLC represents a straightforward way to increase the number of separated compounds in a single two-dimensional run. This option has been evaluated in metabolomics analysis [65] , but this approach has not been applied to the pteridine analysis. The field of HILIC separation using fluorimetric detection opens up new ways in the serum pteridine analysis, and this approach could be an interesting alternative to RP-HPLC. Another focus for future research could be to modify the detection system with the incorporation of serial fluorimetric-electrochemical detectors. Both reduced and oxidized forms could be analyzed with high sensitivity. No data about this approach in serum pteridine analysis have been yet reported.
From our point of view, the study of alternative oxidation processes, instead of chemical oxidation, appears as an interesting research way. In addition, the possibility of coupling the oxidation system online appears to be adequate to diminish human intervention, contamination of the samples, sampler frequency and dilution of the samples. This aspect could be merged in a coupled postcolumn online photooxidation system. This photosystem could work in an on/off mode; hence, in the off-mode, oxidized pteridines could be fluorimetrically detected directly and in the on-mode, reduced forms should generate fluorescent forms and then fluorimetrically detected. The literature about this approach has been reported in the analysis of healthy and pathological urine samples [14] (Figure 5 ), but it has not yet been applied in serum samples. With this approach, reduced and oxidized forms could be analyzed in serum samples using the high sensitivity of fluorimetric detection. This research is currently carried out.
Chemometric methods are a novel tool that are being implement in biological fluid analysis with satisfactory prospects, and in the future, could be an alternative to chemical separation of the analytes from complex matrices such as urine and serum. The interference of the complex matrix can be mathematically modulated using selected mathematical algorithms. An ideal chromatographic experiment should lead to perfect separation of the analytes, but it is not possible at times and overlapping peaks result. In these cases, multivariate data analysis can be used for achieving selectivity by mathematical means.
Second-order multivariate calibration can be performed when full selectivity in the chromatographic separation is not achieved [66] , even in the presence of unexpected components. It is interesting to note that, to date, very few works regarding HPLC with fast-scanning fluorescence detection (HPLC-FSFD) second-order data have been reported. First, an approach to determine five of the most important pteridine markers (BIO, NEO, ISO, XAN and PT) by means of a chromatographic method linked to a second-order multivariate procedure has been reported. The developed method enables the determination of the listed pteridines in urine, some of them with overlapping profiles, in a short analysis time and with the consequent reduction of reagent consumption [67, 68] . A multivariate curve resolution-alternating least squares (MCR-ALS) algorithm gives good results for the investigated system, where significantly overlapped signal are detected. These chemometric approaches could be tested as a powerful tool in conjunction with fluorimetric HPLC in the analysis of serum.
Concluding remarks
The technique of HPLC with fluorimetric detection remains one of the most used techniques in the determination of pteridines in biological fluids, although its main application has been in urine samples, its use in the analysis of serum being significantly lower. Despite the disadvantage of transforming the reduced pteridine forms into oxidized forms for generating fluorescence, fluorescent detection is still an interesting detection mode due to its high sensitivity, unimproved by techniques that exhibit greater identification capability such as MS, although also more expensive.
Recently, a HPLC-hybrid quadrupole time-of-flight (QTOF) MS method has been reported for intracellular pteridine detection [13] . This technique avoids the prior oxidation step and the reduced forms are protected using DTT. Seven intracellular pteridines have thus been determined. The detection limits are in the range of 0.1-3 μg L −1
. In accordance with these values, the sensitivity of the proposed LC-MS method is not comparable with that reported by HPLC-fluorimetric detection, summarized in Table 2 . On the other hand, reduced pteridine forms were not found in intracellular media. Presently, the use of a more expensive technique such as LC-MS does not appear to resolve the two main problems in the analysis of pteridines in biological fluids: 1) Allowing the determination of the pteridines in the original oxidation state and 2) Providing the high sensitivity required in the clinical applications and biochemical studies. Therefore, researchers continue proposing different methods to transform the reduced forms to fluorescent oxidized forms, such as chemical oxidation with different agents, photooxidation, electrochemical oxidation, etc. Also, some of these processes have even been semiautomated through online systems coupled to chromatographic systems, but there is still no consensus on the best way to do it.
From a standpoint of clinical use, setting the pteridinic serum content would be essential to compare the results obtained from several researchers and between healthy and pathological individuals. Currently, data about the levels of pteridines in serum are scarce, and most data refer only to NEO and BIO, but do not cover the rest of pteridines present; mismatched data also exist. On the other hand, in order to achieve comparable data, it is necessary to conduct a similar pretreatment of the samples, and at present, comparable data are not present.
We believe that research into the development of new methods that would allow us to analyze pteridines in their naturally present forms, both fluorescent and non-fluorescent, in the same sample and with sufficient sensitivity is essential.
